Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
DiaMedica Therapeutics Inc. (DMAC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: " "
05/18/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: " "
05/15/2023 8-K Quarterly results
Docs: " "
03/28/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/06/2023 8-K Resignation/termination of a director
Docs: " "
11/09/2022 8-K Quarterly results
10/26/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
07/06/2022 8-K Quarterly results
06/29/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
03/14/2022 8-K Quarterly results
Docs: " "
02/11/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: " "
09/27/2021 8-K Quarterly results
09/13/2021 8-K Quarterly results
08/11/2021 8-K Quarterly results
07/16/2021 8-K Quarterly results
06/29/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
04/29/2021 8-K Other Events
03/10/2021 8-K Quarterly results
11/04/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "DiaMedica Therapeutics Inc. Consolidated Statements of Operations and Comprehensive Loss Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Operating expenses: Research and development $ 2,180 $ 1,617 $ 5,190 $ 6,098 General and administrative 1,139 1,044 3,241 2,725 Operating loss Other expense: Governmental assistance - research incentives Other expense, net 38 Total other income Loss before income tax expense Income tax expense 2 12 20 29 Net loss Other comprehensive income Unrealized gain on marketable securities 8 6 Net loss and comprehensive loss $ $ $ $ Basic and diluted net loss per share $ $ $ $ Weighted average shares outstanding – basic and diluted 16,689,074 12,006,874 14,652,749 11,981,233 DiaMedica Therapeutics Inc. Consolidated ..."
08/11/2020 8-K Quarterly results
08/07/2020 8-K Quarterly results
08/05/2020 8-K Quarterly results
06/03/2020 8-K Submission of Matters to a Vote of Security Holders, Other Events
05/13/2020 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "DiaMedica Therapeutics Inc. Consolidated Statements of Operations and Comprehensive Loss Three Months Ended March 31, 2020 2019 Operating expenses: Research and development $ 1,381 $ 2,607 General and administrative 1,023 814 Operating loss Other expense: Governmental assistance - research incentives Other expense, net 127 Total other expense 12 Loss before income tax expense Income tax expense 9 9 Net loss Other comprehensive income Unrealized gain on marketable securities 40 3 Net loss and comprehensive loss $ $ Basic and diluted net loss per share $ $ Weighted average shares outstanding – basic and diluted 13,107,725 11,956,874 DiaMedica Therapeutics Inc. Consolidated Balance Sheets ASSETS Current assets: Cash and cash equivalents $ 3,300 $ 3,883 Marketable securities 9,348 3,995 ...",
"Investor Contact",
"Investor Presentation issued by DiaMedica Therapeutics, Inc. in connection with the release of its top-line results of its Phase II ReMEDy trial (furnished herewith)"
03/23/2020 8-K Quarterly results
02/13/2020 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and between DiaMedica Therapeutics Inc. and Craig-Hallum Capital Group LLC (filed herewith)",
"Opinion of Pushor Mitchell LLP (filed herewith)",
"DiaMedica Announces Pricing of Public Offering of Common Shares"
02/11/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy